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The promoter of the human proto-oncogene MYC has been the first cellular target shown to be subject to regulation by the E2F transcription 
factor. E2F also has binding sites in other promoters regulated by cell proliferation and during the cell cycle. We have analyzed Saccharomyces 
cerevisiae for the presence of an E2F-analogous protein. GALl-based promoter constructs carrying the E2F binding site of the MYC or the 
adenovirus E2 promoter showed transcriptional activity in yeast cells. A DNA-binding factor, designated YE2F, binds specifically to the E2F 
consensus equence and was partially purified from yeast extracts. YEZF showed identical contact points within the MYC binding site as authentic 
E2F protein from mammalian cells. The results suggest he existence of an EZF-like protein in the yeast S. cerevkae. 
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1. INTRODUCTION 
Transcription factors are of critical importance for 
the tissue- and differentiation-specific transcription of 
eukaryotic genes. These factors determine the frequency 
of transcription initiation by interacting specifically 
with regulatory DNA elements [ 1,2]. Recently it became 
clear that, apart from sequence-specific DNA interac- 
tions, transcription factors may also interact with other 
proteins. Such proteins include other transcription fac- 
tors, factors of the common transcription machinery, or 
proteins which are able to cooperate with or dissociate 
such transcription initiation complexes, but themselves 
do not bind to DNA. 
E2F [17]. Alterations in the composition of E2F com- 
plexes may therefore play a role in El A-mediated onco- 
genesis [181. 
In this context much attention has been given to the 
regulation of the cellular proto-oncogene MYC. The 
cellular transcription factor E2F was found to bind effi- 
ciently to an element within the P, promoter [4]. Binding 
of E2F is essential for basic expression and for transac- 
tivation of the PZ promoter by adenovirus ElA protein 
[19,20]. 
E2F was originally identified as a cellular transcrip- 
tion factor involved in the regulation of adenovirus 
early promoters and enhancers by interacting with the 
virus-encoded early ElA protein [3]. Besides the c-myc 
gene [4] there are now several more cellular E2F-bind- 
ing sites known, for example in the promoters of the 
DNA polymerase 01 [5], a histone H2A-H2B gene pair 
[6] and the hamster DHFR gene [7]. It has been shown 
recently that E2F forms complexes not only with the 
adenovirus E&gene product [8,9], but also with impor- 
tant cellular proteins like cyclin A [lo], cdk2 kinase [ 1 I], 
the tumor suppressor gene product RB [12-141 and an- 
other protein, ~107, closely resembling RB [ 15,161. Viral 
antigens such as adenovirus ElA, papillomavirus E7 
and SV40 large T-antigen are capable of dissociating 
these complexes and therefore change the activity of 
We have analyzed the yeast Saccharomyces cerevisae 
for the presence of E2F-analogous proteins by using 
GAL l-based promoter constructs with E2F binding 
sites of the MYC PZ promoter or the adenovirus E2 
promoter. We report here the existence of a factor spe- 
cifically binding to the E2F consensus sequence. The 
partially purified protein, designated YE2F, behaves 
like authentic E2F isolated from mammalian cells as 
shown by its effects on transcription, protection and 
contact point analyses. 
2. MATERIALS AND METHODS 
2.1. Yeast strains and media 
For all experiments the S. cerevisiae strain MGDL4a (leu2, ura3, 
his3, trpl, lys2, cyh’, MATa) was used. Yeasts were grown at 30 ‘C 
in YPD, containing 2% glucose, or in selection medium lacking uracil. 
2.2. Plasmids 
For the transcription activation tests oligonucleotides with wild- 
type and mutated E2F-binding sites were cloned in the XhoI site of 
pLRld1 [21] (see Fig. 1). For the footprint experiments the oligonucle- 
otide MYC-wt’ was cloned into pBluescript o yield pBSM910. The 
bacterial strain used routinely for cloning was E. coli DH5& [22]. 
Correspondence address: M. Lipp, Institut fiir Biochemie der Ludwig- 
Maximilians-Universitat Miinchen, Am Rlopferspitz 18a, D-8033 
Martins&d, Germany. Fax: (49) (89) 8578 2470. 
2.3. Preparation and pwijication of yeast extracts 
Yeasts were grown in YPD medium to ODm, = 1, harvested by 
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centrifugation and suspended in 11100 vol. of a buffer containing 25 
mM HEPES pH 7.5, 1 mM DTT and 15% glycerol. Protein extracts 
were prepared by incubation with Zymolyase-1OOT (Miles Scientific) 
(1 mg/g cell pellet) for 3&60 min at 37’C. After two centrifugations 
at 20,000 rpm the supematant was stored as crude extract at -80°C 
or loaded onto a DEAE-Sepharose CMB column (Pharmacia) equil- 
ibrated with buffer FA (40 mM HEPES pH 7.5,l mM EDTA, 1 mM 
DTT, 15% glycerol) containing 100 mM NaCl. After washing with 3 
~01s. buffer FA containing 100 mM NaCl proteins were eluted with 
a linear gradient from 0.1 to 1 M NaCl in buffer FA. Active fractions 
(0.4-0.7 M NaCl) were pooled, diluted to 200 mM NaCl and loaded 
onto a Heparin-Sepharose or a FPLC-MonoQ column (Phannacia) 
equilibrated with buffer FA containing 100 mM NaCl. After washing 
with 2 ~01s. buffer FA containing 100 mM NaCl proteins were eluted 
with a linear gradient from 0.1 to 1 M NaCl in buffer FA. Active 
fractions (0.5-0.6 M NaCl in the case of MonoQ; 0.7-0.8 M NaCl in 
the case of Heparin-Sepharose) were stored at -80 “C. 
2.4. Yeast transformation and /3-galactosiabse assay 
Yeast cells were transformed with 3-5 pug DNA of each construction 
by the LiAc technique [23] and transformants were selected on selec- 
tion medium lacking uracil. Fresh transformants were used to inocu- 
A 
-9s 
I -66 E2F -:a 
late liquid selection medium and protein extracts were prepared at 4°C 
with a bead mill (Retsch), centrifuged at 15,000 rpm and stored at 
-8OOC. /?-Galactosidase assays were performed from at least three 
independent transformants and repeated at least four to six times as 
previously described [24]. p-Galactosidase units presented are aver- 
ages from multiple assays. 
2.5. Gel retardation assay 
Gel retardation assays were performed as described by Schneider 
[25]. A reaction volume of 30 ~1 usually contained 50 fmol of double- 
stranded oligonucleotide nd-labeled by Klenow polymerase, 1 pg 
poly[d(A-T)], 200 ng sonicated salmon sperm DNA, 40 mM HEPES 
pH 7.5,lO mM MgCl,, 100 mM NaCl and up to 2Opg of protein. The 
binding reaction was carried out for 10 min at room temperature. 
DNA-protein complexes were separated from free DNA on 8% poly- 
acrylamide gels running in 0.5 x TBE. 
2.6. Methylation ititerference footprint analysis 
The 72-bp EamHVPstI fragment from pBSM910 was isolated, end- 
labeled with reverse transcriptase and methylated partially with di- 
methylsulfoxide (DMSO) [26]. Gel retardation experiments, caled up 
20- to 30-fold, were performed with the DMSO-treated probes. DNA- 
-26 
5’ - CTCGACiAAGGGCAGGGCTTCT,CAGAGGCT 
- 
BGAACGGAGGGAGGGAT~GCGCTGAO[ - 3 0 MYC P2-promoter 
.w,* t L . . . I a... 
a... MYC-W,+ /,..-* _....- %._ -... *... -.. <.* “,/ 
/ 
pLRlA1 
Adenovirus 
E2 promoter 
@TTCGCGCHGCGCGN~A& d-w+ 
.jx ~TTCGCGCHGCGCGAA~) Ad-W IV 
(rTTCnaGCHGCttGA&j Ad-ml- 
O-galactosldase activity (units / mg) 
Fig. 1. Transactivation of GAL1 based promoter constructions mediated by E2F binding sites from the human MYC P2 promoter and the 
adenovirus E2 promoter. (A) Sequence of the human MYC P2 promoter and the adenovirus E2 promoter with the derived wild-type-oligonucleotides 
which were cloned into the Xho I site of the reporter plasmid pLRld1 [19]. (B) Average/?-galactosidase. units/mg protein for the constructions with 
the wild-type and mutated E2F binding sites. Boxes show the upper strand of the binding site with small letters for the exchanges in the E2F binding 
site. Black triangles depict the orientation of the binding sites with respect o the wild-type situation. T’he broken line marks the vector background. 
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protein complexes were excised, the DNA isolated with electro-iso- 
tachophoresis [271 and purified by ethanol precipitation. After treat- 
ment with N&Cl and piperidine [26] the DNA was analyzed on a 8% 
urea sequencing el. As reference we used a Maxam-Gilbert sequence 
of the same probe. 
2.7. DNase I protection analysis 
The fragment was labeled as described above. A gel retardation 
reaction mix was scaled up 20-fold. After incubation for 10 min on ice 
DNase I was added to a final concentration of 100 to 300 @ml. After 
1 min incubation at 37°C DNA-protein complexes and free DNA 
were separated on a 8% polyacrylamide gel. Shifted DNA was excised 
and eluted as described above. Positions of DNase I cleavage sites 
were determined by coeletrophoresis of Maxam-Gilbert sequencing 
reaction of the same probe on a 8% urea sequencing el. 
2.8. Renaturation of proteins 
Partially purified extracts were run on a 16% Tricine-gel PSI, the 
gel was cut in small (1-2mm) horizontal sections, and the proteins of 
these strips were eluted in an elution buffer (50 mM Tris pH 7.9,0.1% 
SDS, 0.1 mg/ml BSA, 1 mM DTT, 0.1 mM PMSF, 2.5% glycerol) 
overnight at 4°C. The supematant was precipitated with 5 ~01s. meth- 
anol/acetone at -8O’C for at least 2 h. The dry pellet was dissolved 
in renaturation buffer (20 mM Tris pH 7.6,150 mM urea, 10 mM KCl, 
2 mM DTT, 10 PM PMSF). After at least 12 h at 4°C the renatured 
proteins were tested for DNA binding in the gel retardation assay or 
loaded on a 16% Tricine-gel to determine their size. 
3. RESULTS AND DISCUSSION 
In view of the interactions of E2F with proteins in- 
volved in growth regulation and the cell cycle (Rb, ~107, 
Cyclin A, cdk2) and the fact that many important pro- 
teins are conserved between yeasts and higher eukaryo- 
tes the presence of an E2F-like activity in the yeast 
Saccharomyces cerevisiae would not be surprising. This 
assumption is also supported by the observation that a 
number of Scervisiae genes contain potential E2F- 
binding sites (see Table I). 
3.1. Yeast E2F activates transcription in vivo 
To investigate whether the E2F-specific binding sites 
are functional in yeast cells, we cloned oligonucleotides 
carrying the wildtype E2F-binding site from the MYC- 
Pz promoter, the adenovirus EZpromoter or different 
mutations of the binding sites in various copy numbers 
and orientations into the reporter plasmid pLRld1 [21]. 
This plasmid carries a GALl/lacZ-fusion-gene under 
the control of the GALlO/GALl-intergenic region, 
from which the UAS-element has been removed (Fig. 
1). Most oligonucleotides were inserted in both orienta- 
tions. These constructions were used for transformation 
of yeast cells. As shown in Fig. 1 only the E2F wildtype- 
binding sites yielded significant expression of the re- 
porter-gene. On comparison with the negative control 
- vector without binding site oligonucleotide - the tran- 
scription activity was more than six times higher for one 
E2F-binding site (MYC-P, or Ad E2 promoter), more 
than twelve times higher for the inverted orientation 
(MYC-P, promoter) and nearly forty times 
higher for the triple-binding site construction. The repe- 
tition of four double-E2F-binding sites from the adeno- 
virus E2 promoter yielded the strongest ranscriptional 
activation. The sequence around the E2F-binding site 
or a mutated binding site only resulted in a weak tran- 
scriptional activation (at most 4-fold for construction 
MYC-mS+). Both E2F-binding sites, from the MYC-P, 
and the adenovirus E2 promoter showed comparable 
stimulatory activities when they were inserted as single 
copies (Fig. 1). The higher transcriptional stimulation 
for the MYC-wt- construction with an inverted E2F- 
binding might be explained by a more favourable con- 
formation of the bound protein and the RNA polym- 
erase or accessory proteins. The presence of multiple 
binding sites led to a dramatic increase in /I-galactosi- 
Table I 
Potential EZF-binding site in S. cerevisiae promoter sequences 
Gene ID Sequence and location 
Phosphogycerate kinase UAS 
Growth regulation protein (WHI2) 
Ribosomal protein 29 
Mitochondrial ribosomal protein L8 
Alcohol dehydrogenase (ADR2) 
Sporulation and meiosis segregation gene 
Putative Gl cyclin (HCS26) 
Histon H4 
Ribosomal protein L44 
Recombination gene (RAD54A) 
Casein kinase I 
CAMP-dependent kinase 
SCPGKUAS -358 
scwH12 -17 
SCRP29 -232 
SCMRPLE -123 
SCADRZ -348 
SCREDl -436 
SCGlCYC -306 
SCH3H402 -266 
SCRGAP44 -203 
SCRAD54A -67 
SCYCKl -32 
SCTPKA -338 
atGGCGGGAAAggg 
ctGGCGGGAAAtta 
taGGCGGGAAAtaa 
gaGGCGGGAAAagt 
caGGCGGGAAAcca 
gtcGCGGGAAActt 
CcgGCGCGAAAttt 
CggGCGCGAAAtgc 
gacGCGCGAAAcca 
tttGCGCGAAActt 
aatGCGCGAAAttt 
ataGCGCGAAAaaa 
-345” 
-30” 
-245” 
-1lOb 
-335b 
-429” 
-293b 
-253b 
-190” 
-80 
-45b 
-351b 
a position relative to the transcription start 
b position relative to the ATG 
The EMBL Nucleotide Sequence Database, Release 31 (June 1992) was searched for potential EZF-binding sites (GGCGGGAAA and 
GCGCGAAA). The listed sequences are a selection of E2F-binding sites which lay upstream of the transcription start or the start codon of 
Saccharomyces cerevisiae genes. 
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A Heparin-Sepharose 0.8 M NaCl 
probe 
I , 
MYC-wt+ MYC-m 
YEPF 
free 
probe 
B 
E2F 
GAACGGAGGGAGGGAT MYC-wt+ 
MYC-ml+ 
E2F E2F 
TCGAG TTCGCG TTAAATTTGAGAAAG 
C 8-g qrv Ad-wt+ AAGCGC ATTTAAACTCTTTC GCGCTT AGCT 
TCGAG TTCaaG TTAAATTTGAGAAAG 
$-$ $f$ Ad-ml+ C AAGttC ATTTAAACTCTTTC GaaCTT AGCT 
SWI 416 
CYC-pro 
Fig. 2. Gel retardation, using a partially purikd yeast extract, shows 
a YE2F-specific complex. (A) A Heparin-Sepharose gradient fractions 
was tested for the presence of a YE2F-specific complex. The sequence 
of the probe and the competitor oligonucleotides are shown in (B), 
with the E2F- or SW1 4/6-binding site in boxes and the mutations in 
small letters. MYC-wild-type and a MYC mutant oligonucleotide 
were used as probes for the binding reaction. All oligonucleotide- 
competitors were present in 60-fold molar excess. The first lane shows 
a reference binding reaction with no protein. 
dase activity. This behaviour suggests a cooperative 
binding of the yeast E2F-like activity, and this is in good 
agreement with the observations made with the mam- 
malian E2F [31]. 
3.2. Specific binding pattern of an E2F-analogous pro- 
tein in yeast cell extracts 
3.4. The YE2F-specijic binding actiyity has a size of 
= 12 kDa and does not appear to exist as a hetero- 
complex 
In order to further investigate the putative E2F-anal- Since human E2F forms complexes with several other 
ogous protein we have used the technique of gel retarda- proteins we also investigated whether the YE2F-specific 
tion. The end-labeled ouble-stranded oligonucleotides DNA-protein complex consisted of hetero-complexes. 
MYC-wt’ and MYC-ml’(Fig. 2) were routinely em- We separated a partially purified yeast extract through 
ployed as probes for analyzing DNA-protein com- a denaturing Tricine-SDS gel and cut the gel into hori- 
plexes. With this test we partially purified a yeast crude zontal stripes to obtain after elution and renaturation 
extract, by using a combination of DEAE-Sepharose, fractions of proteins with different sizes, the molecular 
MonoQ and Heparin-Sepharose columns. As shown in weights of which were determined on denaturing 
Fig. 2, a gradient fraction of a Heparin-Sepharose run 
gave rise to only one specific DNA-protein complex 
(indicated with YE2F). The specificity of the complexes 
was demonstrated by competition analysis with a 60- 
fold excess of unlabeled oligonucleotides. The only 
competing oligonucleotides were those carrying a 
wildtype E2F-binding site from the MYC-P, promoter 
or the adenovirus E2 promoter. Neither oligonucleo- 
tides with mutated binding sites nor an oligonucleotide 
with a SW1 4/6 binding site from the CLN2 promoter 
[29] were able to prevent the formation of YE2F-DNA 
complexes. These demonstrates that there is no relation- 
ship between YE2F and the SWI 4/6 complex, although 
the E2F-binding site possesses ome homologies to the 
SW1 416 binding sequence [29]. Probe MYC-ml’, which 
does not contain an E2F-binding site, did not result in 
DNA-protein complex formation with the same extract 
(Fig. 2). This shows that the sequences urrounding the 
E2F-binding site are not responsible for the formation 
of the YE2F-DNA complex. The same results were ob- 
tained with yeast crude extracts (data not shown). In 
contrast to the gel retardation pattern of mammalian 
E2F, which gives rise to several specific complexes 
[4,32], yeast E2F only forms one specific complex, in 
crude extracts as well as in partially purified extracts. 
Since the different mammalian E2F complexes are due 
to interactions of E2F with other proteins [g--16], our 
results suggest that in the yeast system no similar inter- 
actions take place. 
3.3. Yeast E2F interacts with the human MYC-P, pro- 
moter 
To confirm the data obtained by gel retardation and 
competition experiments we p rformed methylation in- 
terference- and DNaseI-footprint analyses. In the se- 
quence pattern of the complexed DNA, which has 
shown a YE2F-specific competition pattern, five G and 
two A residues interfered with protein binding after 
methylation (Fig. 3B). The DNase I-protected region 
clearly included the complete E2F-binding site (Fig. 
3A). This indicated that the sequence GGCGGGAA is 
essential to form the YE2F-specific complex. These re- 
sults prove conclusively that an E2F-analogous protein 
or a transcription factor with a similar recognition se- 
quence exists in the budding yeast. 
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Volume 321, number 2,3 FEBS LETTERS April 1993 
C 
YEZF 
-80 
L 
protected regm” 
Fig. 3. DNaseI protection and methylation interference assay with 
partially purifled yeast extract. (A) The oligonucleotide MYCwt’ was 
cloned into pBluescript. After an upscaled gel retardation assay the 
DNA of the YEZF-specific band and the free probe were isolated and 
run on a sequencing el. As reference the Maxam-Gilbert sequence 
of the same fragment is shown (> = G > A reaction; U = purines; 
Y = pyrimidines). The - lane contains the DNasel digest of a reaction 
with no protein. The boxed sequence marks the E2F-binding site of 
the MYC-P, promoter. The brackets show the DNase I-protected 
region when YE2F is bound to the DNA. (B) The same labeled 
fragment was partially methylated with dimethylsulfate (DMS) in a 
G > A reaction and incubated with partially purified yeast extract. 
Beside the Maxam-Gilbert sequence (Y = pyrimidines; U = purities 
> = G > A reaction) the interference pattern of the free and bound 
DNA is shown. G and A nucleotides that interfere with YEZF-binding 
are indicated with black triangles. (C) MYC-P, promoter sequence 
from -80 to -45 with the EZF-binding site boxed. The black triangles 
indicate the G and A nucleotides which interfere with the binding of 
YEZF and the brackets show the DNase I-protected region. 
Tricine-SDS gels (Fig. 4A). To determine which size 
fractions contained the YEZF-specific binding activity 
we assayed the renatured proteins with the standard gel 
retardation assay (Fig. 4B). Only one size fraction, from 
11.1 to 12.0 kDa, yielded material that formed a YE2F- 
specific complex. In renaturation experiments with 
crude yeast extracts we obtained exactly the same size. 
DNA-protein complexes observed in higher size frac- 
tions were shown to be results of unspecific DNA-pro- 
tein interactions as determined by competition experi- 
ments (data not shown). So the data from the renatura- 
tion experiments corroborate the results of gel retarda- 
tion experiments: firstly the very fast migrating DNA/ 
protein complex makes it very likely that a small protein 
is responsible for complex formation; secondly the com- 
plex consists of a single protein or an homodimer and 
not an heterodimer of YE2F and another protein. The 
size of YE2F (- 12 kDa) is smaller than that of other 
known yeast DNA-binding proteins such as MCBF 
(MU-cell cycle box-binding factor; [333), MBF (MluI- 
cell cycle box-factor; [34]) and DSCI (DNA synthesis 
control; [35]). These three proteins were shown to bind 
a similar sequence (S-ACGCGCT-3’) and mediate cell 
cycle-regulated expression of genes. With South-West- 
ern analysis it was shown that MCBF has an apparent 
molecular weight of 17 kDa and MBF of approximately 
120 kDa, whereas YEZF has a size of = 12 kDa. Perhaps 
this 12 kDa protein is only a degradation product but 
the migration behaviour in the gel retardation assay did 
not change during the purification procedure and the 
size determinations from crude extracts and partially 
purified extracts revealed exactly the same size. Alternar 
tively the nature of the interaction of YE2F with other 
putative partners could be extremely weak and there- 
kDa 
Fig. 4. Determination of the size of the YE2F activity with a protein 
renaturation experiment. (A) The size fractions of the renatured pro- 
teins were separated again on a denaturing 16% Tricine gel and silver 
stained. The strong band at approximately 66 kDa and the sometimes 
visible weak bands down to this occuring in each lane correspond to 
the BSA of the elution buffer. The boundaries of the size areas were 
determined with a standard curve using the shown marker proteins as 
fixed size-points. (B) The same size fractions were assayed for the 
existence of DNA-binding proteins. Binding reactions were done as 
described above and separated on a 8% native polyacrylamide gel. The 
size area of the proteins inserted in each binding reaction is indicated 
above each lane. The position of the free probe and the YEZF-specific 
complex is marked with arrows. The other complexes are unspecific. 
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fore not detectable by gel retardation assay. Neverthe- 
less this small protein is responsible for a highly specific 
recognition of an E2F binding site. 
3.5. The YE2Pspecific binding activity does not change 
during the cell cycle 
Since it is known from the mammalian E2F, that its 
DNA-binding and transactivation potential is regulated 
through the cell cycle [ 11,161 we investigated if there are 
any changes of the YE2F binding activity through the 
cell cycle. Therefore we synchronized an appropriate 
barl- yeast strain with a-factor treatment as previously 
described by Rhode [36]. The synchronization was con- 
trolled by FACS-analysis and protein extracts from the 
different cell cycle stages were tested with the gel retar- 
dation assay. But we did not find any significant 
changes through the cell cycle on protein level. So far 
there is only the DSCI-factor known to be regulated 
through the cell cycle detectable on protein level [36]. 
However as long as the YE2F-gene isn’t cloned we 
could not analyse its product at the RNA-level. Since 
in 1992 a mammalian E2F-like gene was cloned [37,38] 
it should be possible to find the homologous gene in 
yeast. Cloning of the gene coding for YE2F will allow 
to analyse its regulation and function in Saccharomyces 
cerevisiae in more detail, as well as to evaluate which 
functional domains of YEZF may be evolutionarily con- 
served. 
Acknowledgements: We thank Georg Arnold for the synthesis of ol- 
igonucleotides and Horst Bxlgaufts and Ingrid Wolf for critically 
reading the manuscript. B.M. was supported by a doctoral fellowship 
from the ‘Boehtinger Ingelheim Fonds’. The work was supported by 
the Deutsche Forschungs Gemeinschaft Forschergruppe ‘Virus-Zell- 
Wechselwirkung’ (FA 138/3-7). 
REFERENCES 
[II 
;:; 
[41 
[51 
wl 
[7l 
[81 
Johnson, P.F. and M&night, S.L. (1989) Annu. Rev. Biochem. 
58, 799-839. 
Latchman, D.S. (1990) B&hem. J. 270, 281-289. 
Kovesdi, I., Reichel, R. and Nevins, J.R. (1986) Cell 45,219-228. 
Thalmeier, K., Synovzik, H., Mere, R., Winnacker, E. and Lipp, 
M. (1989) Genes Dev. 3, 527-536. 
Pearson, B.E., Nasheuer, H. and Wang, T.S. (1991) Mol. Cell. 
Biol. 11, 2081-2095. 
Dobner, T., Wolf, I., Mai, B. and Lipp, M. (1991) DNA Sequence 
L409-413 
Blake, M.C. and A&khan, J.C. (1989) Mol. Ceil. Biol. 9,4994- 
5002. 
Reichel, R., Neill, S.D., Kovesdi, I., Simon, M.C., Raychaudhuri, 
P. and Nevins, J.R. (1989) J. Virol. 63, 3643-3650. 
[9] Raychaudhuri, P., Bag&i, S., Neill, S.D. and Nevins, J. R. (1990) 
J. Virol. 64, 2702-2710. 
[lo] Mudryj, M., Devoto, S.H., Hiebert, S.W., Hunter, T., Pines, J. 
1111 
1121 
1131 
[I41 
[I51 
WI 
[I71 
and Nevins, J.R. (1991) Cell 65, 1243-1253. 
Pagano, M., Draetta, G. and Jansen-Diirr, P. (1992) Science 255, 
1144-l 147. 
Chellapan, S., Hiebert, S., Mudryj, M., Horowitz, J.M. and Nev- 
ins, J.R. (1991) Cell 65, 1053-1061. 
Bagchi, S., Weinmann, R. and Raychaudhuri, P. (1991) Cell 65, 
1063-1072. 
[I81 
I191 
[201 
f211 
1221 
1231 
~241 
~251 
[261 
~271 
Chittenden, T., Livingston, D.M. and Kaelin, W.G.J. (1991) Cell 
65, 1073-1082. 
Cao, L., Faha, B., Dembski, M., Tsai; L., Harlow, E. and Dyson, 
N. (1992) Nature 355, 176-179. 
Shirodkar, S., Ewen, M., DaCaprio, J.A., Morgan, J., Living- 
ston, D.M. and Chittenden, T. (1992) Cell 68, 157-166. 
Chellappan, S., Kraus, V.B., Kroger, B., Munger, K., Howley, 
P.M., Phelps, WC., Nevins, J.R. (1992) Proc. Natl. Acad. Sci. 
USA 89,4549-53. 
Bag&i, S. and Raychaudhuri, P. (1990) Cell 62, 659669. 
Hiebert, SW., Lipp, M. and Nevins, J.R. (1989) Proc. Natl. 
Acad. Sci. USA 86, 3594-3598. 
Lipp, M., Schilling, R. and Bernhard& G. (1989) Gncogene 4, 
535-541. 
West, R.W., Yocum, R.R. and Ptashne, M. (1984) Mol. Cell. 
Biol. 4, 2467-2478. 
Wood, W.B. (1966) J. Mol. Biol. 16, 118-133. 
Ito, H., Fukuda, Y., Murata, K. and Kimura, A. (1983) J. 
Bacterial. 153, 163-168. 
Rose, M.D., Novick, P., Thomas, J.H., Botstein, D. and Fink, 
G.R. (1987) Gene 60, 237-243. 
Schneider, R., Gander, I., Miiller, U., Mertz, R. and Winnacker, 
E.L. (1986) Nucleic Acids Res. 15, 1303-1317. 
Maxam, A.M. and Gilbert, W. (1980) Methods Enzymol. 65, 
499-560. 
1281 
~291 
[311 
1321 
1331 
Ofverstedt, L.G., Hammerstrom, K., Balgobin, N., Hjeten, S., 
Pettersson, U. and Chattopadhaya, J. (1984) Biochim. Biophys. 
Acta 782, 120-126. 
Schiigger, H. and von Jagow, G. (1987) Anal. B&hem. 166, 
368-379. 
Ogas, J., Andrews, B.J. and Herskowitz, I. (1991) Cell 66,1015- 
1026. 
Pidder, J.D., Boeuf, H. and Kedinger, C. (1989) EMBO J. 8, 
3365-3370. 
Hiebert, S. W., Chellappan, S.P., Horowitz, J.M. and Nevins, J.R. 
(1992) Genes Dev. 6, 177-185. 
Verma, R., Patapoutian, A., Gorgon, C.B. and Campbell, J.L. 
(1991) Proc. Natl. Acad. Sci. USA 88, 7155-7159. 
[34] Dirick, L., Moll, T., Auer, H. and Nasmyth, K. (1992) Nature 
357, 508-513. 
[35] Lowndes, N.F., Johnson, A.L. and Johnson, L.H. (1991) Nature 
350,247-250. 
[36] Rhode, P.R., Elsaesser, S. and Campbell, J.L. (1992) Mol. Cell. 
Biol. 12, 1064-1077. 
[37] Helin, K., Lees, J.A., Vidal, M., Dyson, N., Harlow, E. and 
Fattaey, A. (1992) Cell 70, 337-350. 
[38] Kaelin, W.G., Krek, J.W., Sellers, W.R., DeCaprio, J.A. , Ajch- 
enbaum, F. , Fuchs, C.S., Chittenden, T. , Blanar, M.A. , Living- 
ston, D.M. and Flemington, E.K. (1992) Cell 70, 351-364. 
158 
